75 completed, 46 terminated, 22 active not recruiting, 16 recruiting. 186 Phase 2, 63 Phase 1, 1 Phase 3.
Follow Metastatic Melanoma: new trials by email Literature Review of Metastatic Melanoma trials Research Report on Metastatic Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer Biospecimen Collection, Cholecalciferol, Computed Tomography - Advanced Hepatocellular Carcinoma, Advanced Melanoma | Phase 2 | Not yet recruiting | University of Southern California | 46 | 2026-11-01 | 2026-09-23 |
| Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases | Phase 1 / Phase 2 | Recruiting | University of Wisconsin, Madison | 15 | 2026-11-01 | 2026-10-30 |
| ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab Nivolumab, Relatlimab, Ipilimumab - Metastatic Melanoma, Advanced Melanoma | Phase 2 | Recruiting | NYU Langone Health | 90 | 2026-04-13 | 2026-08-24 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma Lifileucel - Melanoma (Skin Cancer), Unresectable Melanoma | Phase 2 | Active not recruiting | Iovance Biotherapeutics, Inc. | 24 | 2025-11-28 | 2026-10-01 |
| NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis NovoTTF-200A, Pembrolizumab - Metastatic Melanoma, Melanoma Brain Metastasis | Phase 1 / Phase 2 | Withdrawn | Brown University | 2025-10-30 | 2026-01-02 | |
| Mirdametinib in Patients With Advanced NF1-mutant Melanoma Mirdametinib - Advanced Unresectable Melanoma, Metastatic Melanoma | Phase 2 | Recruiting | Kevin Kim, MD | 10 | 2025-10-13 | 2025-11-19 |
| A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel IOV-3001 - Unresectable Melanoma, Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 42 | 2025-03-11 | 2026-06-15 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma GB1211, Pembrolizumab, Placebo - Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Providence Health & Services | 12 | 2024-02-29 | 2026-09-22 |
| Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma Biospecimen Collection, Cyclophosphamide, Echocardiography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Completed | University of Kansas Medical Center | 11 | 2023-12-21 | 2026-04-30 |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors OBX-115 - Tumor Skin, Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Obsidian Therapeutics, Inc. | 254 | 2023-10-25 | 2026-10-05 |
| Cryoablation+Ipilimumab+Nivolumab in Melanoma Ipilimumab, Nivolumab, Cryoablation - Metastatic Melanoma, Skin Cancer | Phase 2 | Recruiting | Massachusetts General Hospital | 37 | 2023-09-23 | 2026-08-27 |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Pembrolizumab, Encorafenib, Binimetinib - Malignant Melanoma, Metastatic Melanoma | Phase 2 | Completed | Dr. Ronnie Shapira | 1 | 2023-09-05 | 2025-07-22 |
| GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients GR-MD-02, Placebo, Pembrolizumab - Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | Providence Health & Services | 2023-07-01 | 2023-06-06 | |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma [203Pb]VMT01, [212Pb]VMT01, Nivolumab - Recurrent Melanoma (Skin), Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 300 | 2023-06-01 | 2026-10-13 |
| Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors Rigosertib, Pembrolizumab, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 7 | 2023-05-09 | 2026-09-16 |
| Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain Natural Killer Cell Therapy, Temozolomide - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain | Phase 1 / Phase 2 | Recruiting | Kari Kendra | 24 | 2023-03-01 | 2026-06-11 |
| A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). ANV419 - Melanoma (Skin), Cutaneous Melanoma | Phase 1 / Phase 2 | Completed | Anaveon AG | 29 | 2022-12-16 | 2025-08-26 |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 150 | 2022-12-06 | 2026-10-29 |
Showing 20 of 186. Sign in to see all of them.
Melanoma (186) · Neoplasm Metastasis (24) · Skin Neoplasms (19) · Brain Neoplasms (15) · Carcinoma, Non-Small-Cell Lung (11) · Carcinoma, Renal Cell (10) · Neoplasms (9) · Lung Neoplasms (7) · Squamous Cell Carcinoma of Head and Neck (7) · Breast Neoplasms (4) · Kidney Neoplasms (4) · Sarcoma (4) · Uveal Melanoma (4) · Triple Negative Breast Neoplasms (3) · Carcinoma (2)
Neoplasms by Histologic Type (186) · Neoplasms by Site (186) · Neoplasms, Germ Cell and Embryonal (186) · Neoplasms, Nerve Tissue (186) · Neuroectodermal Tumors (186) · Neuroendocrine Tumors (186) · Nevi and Melanomas (186) · Skin Diseases (186) · Skin and Connective Tissue Diseases (186) · Neoplasms (177) · Skin Neoplasms (167) · Pathologic Processes (26) · Pathological Conditions, Signs and Symptoms (26) · Neoplastic Processes (25) · Neoplasms, Glandular and Epithelial (21)
Ipilimumab (34) · Nivolumab (30) · Cyclophosphamide (28) · pembrolizumab (28) · aldesleukin (26) · Interleukin-2 (20) · fludarabine (17) · fludarabine phosphate (15) · Biopsy (10) · Magnetic Resonance Spectroscopy (10) · Temozolomide (10) · CTLA-4 Antigen (9) · Bevacizumab (8) · Radiosurgery (8) · Specimen Handling (8)
National Cancer Institute (NCI) (28) · M.D. Anderson Cancer Center (18) · Iovance Biotherapeutics, Inc. (5) · California Pacific Medical Center Research Institute (4) · Providence Health & Services (4) · Hoffmann-La Roche (3) · Inge Marie Svane (3) · Ludwig Institute for Cancer Research (3) · Massachusetts General Hospital (3) · University of Louisville (3) · Abramson Cancer Center at Penn Medicine (2) · American Regent, Inc. (2) · Apexigen America, Inc. (2) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (2) · Dana-Farber Cancer Institute (2)
United States (146) · Germany (11) · France (10) · Spain (10) · Australia (8) · United Kingdom (8) · Italy (7) · Switzerland (6) · Canada (5) · Israel (5) · Denmark (4) · Poland (4) · Austria (3) · Belgium (3) · Hungary (3)
Steven A Rosenberg, M.D. (12) · Anna Pavlick, DO (2) · Antoni Ribas, MD (2) · Brendan D Curti, MD (2) · Brendan D. Curti, MD (2) · Chiara Matilde Catania, Dr (2) · David R Minor, MD (2) · Hussein A Tawbi (2) · Hussein Tawbi, MD, PHD (2) · Inge Marie Svane, Prof., MD (2) · Isabella C Glitza (2)
PMID 25432172, PMID 32747469, PMID 19538053, PMID 20406835, PMID 20564157, PMID 22028492, PMID 22056381, PMID 22261812, PMID 22555974, PMID 22719881, PMID 22864522, PMID 22932225, PMID 23377668, PMID 23519018, PMID 23728176, PMID 23861247, PMID 23969699, PMID 25062770, PMID 25369488, PMID 25695689, PMID 25891304, PMID 26202595, PMID 27166673, PMID 27622997, PMID 28428882, PMID 28489678, PMID 28915798, PMID 29306769, PMID 29470191, PMID 29510745, PMID 29899062, PMID 30154193, PMID 31401903, PMID 31406564, PMID 32152221, PMID 32192573, PMID 32467299, PMID 33643689, PMID 33661190, PMID 33979178, PMID 33990415, PMID 34413169, PMID 34782430, PMID 34855329, PMID 34887574, PMID 34928709, PMID 35537412, PMID 35880942, PMID 35940183, PMID 36049147
2018 (3), U10CA180888 (3), UM1CA186704 (3), UM1CA186688 (2), UM1CA186689 (2), UM1CA186691 (2), UM1CA186709 (2), UM1CA186716 (2), 2008 (1), 2009 (1), 2014 (1), 2015 (1), 2019 (1), 2025 (1), N01CM00038 (1)